title: T cell response to Hu-D peptides in patients with anti-Hu syndrome.
abstract: The anti-Hu syndrome is the most common paraneoplastic neurologic syndrome but the exact mechanism of immune mediated neuronal injury remains unknown. Anti-Hu antibodies do not appear to play a pivotal role in the pathogenesis of the disease. To assess cell-mediated immunity, we selected 51 peptides from the Hu-D sequence and tested their ability to bind to six common HLA class I molecules. Stable complexes with purified HLA molecules were obtained with 19/51 (37%) selected peptides. Subsequently, the ability of the 19 HLA-binding peptides to stimulate T cells from 10 patients and 10 control subjects was evaluated by detecting IFN-gamma secretion. An anti-peptide T-cell response was observed in 7/10 Hu-positive patients but also in 3/10 control subjects. Overall, a significant T-cell activation occurred in response to 74% (14 out of 19) of the selected peptides in the Hu-positive patients vs. 16% (3 out of 19) in the control group (p < 0.001). In addition, T cells of patients tested within 3 months of the onset of anti-Hu syndrome responded to 82% (14 out of 17) of assessed Hu-D peptides vs. 37% (7 out of 19) in patients tested 1 year or more after developing the syndrome (p < 0.01). Thus, the present study suggests a role of cellular immunity during the course of anti-Hu syndrome.
authors.affiliation: Department of Neurology and INSERM U495, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Rousseau
authors.forename: B
authors.initials: B
authors.lastname: Benyahia
authors.forename: J
authors.initials: J
authors.lastname: Dalmau
authors.forename: F
authors.initials: F
authors.lastname: Connan
authors.forename: J-G
authors.initials: JG
authors.lastname: Guillet
authors.forename: J-Y
authors.initials: JY
authors.lastname: Delattre
authors.forename: J
authors.initials: J
authors.lastname: Choppin
mesh_terms: D018288:Carcinoma, Small Cell / Q000150:complications / Q000276:immunology*; D002478:Cells, Cultured; D051959:ELAV Proteins; D015234:HLA-A Antigens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D007371:Interferon-gamma / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000276:immunology* / Q000378:metabolism; D020361:Paraneoplastic Syndromes, Nervous System / Q000150:complications / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology; D016601:RNA-Binding Proteins / Q000276:immunology* / Q000378:metabolism; D018709:Statistics, Nonparametric; D013577:Syndrome; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
chemical_list: D051959:ELAV Proteins; D015234:HLA-A Antigens; D009419:Nerve Tissue Proteins; D010446:Peptide Fragments; D016601:RNA-Binding Proteins; D007371:Interferon-gamma
references.citation: Neurology. 1995 Oct;45(10):1873-8
references.pmid: 7477985
references.citation: Neurology. 1990 Feb;40(2):219-22
references.pmid: 2405292
references.citation: J Neurol Sci. 2002 Sep 15;201(1-2):9-12
references.pmid: 12163187
references.citation: J Exp Med. 1996 Aug 1;184(2):647-57
references.pmid: 8760818
references.citation: Neurology. 1993 Oct;43(10):2049-54
references.pmid: 8413965
references.citation: Clin Cancer Res. 1998 Nov;4(11):2819-24
references.pmid: 9829748
references.citation: J Neurol Sci. 1999 Mar 1;163(2):159-62
references.pmid: 10371077
references.citation: N Engl J Med. 2003 Oct 16;349(16):1543-54
references.pmid: 14561798
references.citation: Neurology. 1998 Oct;51(4):1146-50
references.pmid: 9781545
references.citation: Int J Cancer. 1997 Jun 11;71(6):932-6
references.pmid: 9185691
references.citation: J Exp Med. 1990 Sep 1;172(3):889-99
references.pmid: 2388036
references.citation: J Neuroimmunol. 2003 Sep;142(1-2):93-100
references.pmid: 14512168
references.citation: Ann Neurol. 1995 Jul;38(1):102-10
references.pmid: 7541976
references.citation: Science. 1996 Apr 5;272(5258):54-60
references.pmid: 8600537
references.citation: Eur J Immunol. 1994 Mar;24(3):777-80
references.pmid: 8125145
references.citation: J Immunol. 2001 May 15;166(10):6164-9
references.pmid: 11342637
references.citation: J Autoimmun. 2000 Dec;15(4):479-84
references.pmid: 11090247
references.citation: Nature. 1994 Jun 23;369(6482):648-52
references.pmid: 7516038
references.citation: Eur J Immunol. 1999 Dec;29(12):3995-4001
references.pmid: 10602009
references.citation: J Neuroimmunol. 2002 Jan;122(1-2):100-5
references.pmid: 11777548
references.citation: Clin Cancer Res. 1997 Feb;3(2):221-6
references.pmid: 9815676
references.citation: Neurology. 1997 Oct;49(4):1156-9
references.pmid: 9339709
references.citation: Ann Neurol. 1999 Feb;45(2):162-7
references.pmid: 9989617
references.citation: J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):266-77
references.pmid: 8877721
references.citation: Lab Invest. 1991 Oct;65(4):412-20
references.pmid: 1921331
references.citation: J Exp Med. 1997 Sep 15;186(6):859-65
references.pmid: 9294140
references.citation: J Immunol Methods. 1996 May 27;191(2):131-42
references.pmid: 8666832
references.citation: Immunol Rev. 1998 Aug;164:139-55
references.pmid: 9795772
references.citation: Neurology. 1998 Jun;50(6):1919
references.pmid: 9633765
references.citation: Nature. 1964 Dec 5;204:998-1000
references.pmid: 14248725
references.citation: Cancer. 1995 Jan 1;75(1):99-109
references.pmid: 7804984